Search results for "STM"

showing 10 items of 1715 documents

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

2009

Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender…

AdultMalemedicine.medical_specialtyMultiple SclerosisPropensity scoreDiseasegender; interferon beta; multiple sclerosis; observational study; propensity scoreLower riskSeverity of Illness IndexMultiple sclerosis Interferon beta Gender Observational study Propensity scoreCohort StudiesDisability EvaluationYoung AdultSex Factorsgender multiple sclerosis treatment interferonDouble-Blind MethodInternal medicineObservational studymedicinegenderConfidence IntervalsOdds RatioProduct Surveillance PostmarketingHumansImmunologic FactorsMultiple sclerosiProportional Hazards ModelsExpanded Disability Status ScaleProportional hazards modelbusiness.industryMultiple sclerosisDrug Administration RoutesInterferon-betamedicine.diseaseInterferon betaSurgeryNeurologyItalyCohortPropensity score matchingRegression AnalysisSettore MED/26 - NeurologiaObservational studyFemaleNeurology (clinical)business
researchProduct

Natalizumab: a country-based surveillance program

2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, and a demonstrated efficacy in decreasing the frequency of relapses and progression of disability in relapsing-remitting multiple sclerosis (RR MS). After the approval of FDA and EMEA in MS cases unresponsive to immunomodulating therapy or in severe MS patients also not previously treated with interferons, and considering the concern on the possible side effects, an accurate program of surveillance was organized in our country by a combined effort of AIFA, Cineca, Department of Pharmacology of University of Bologna, and a group of neurologists appointed by the National Society of Neurology (S…

AdultMalemedicine.medical_specialtyNeurologyDatabases FactualDrug-Related Side Effects and Adverse ReactionsNational Health ProgramsDrug ResistanceDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabInternal medicineOutcome Assessment Health CareMultiple SclerosiPharmacovigilanceProduct Surveillance PostmarketingmedicineAdverse Drug Reaction Reporting SystemsHumansImmunologic FactorsMULTIPLE SCLEROSISNATALIZUMABClinical Trials as Topicbusiness.industryMultiple sclerosisAntibodies MonoclonalMean ageGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyREGISTRYPHARMACOVIGILANCEPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessPreviously treatedFollow-Up Studiesmedicine.drug
researchProduct

Electromyographic and patient-reported outcomes of a computer-guided occlusal adjustment performed on patients suffering from chronic myofascial pain

2014

Objectives: Muscular hyperactivity is a potential source of symptoms in patients with temporal-mandibular disorders. An adequate occlusal adjustment may relieve such symptoms. This study aims to measure the effect of shortening the protrusive disclusion time (DT) and balancing the center of occlusal forces (COF) on the EMG recordings and assess the pain reported by chronic patients one month after the computer-guided occlusal adjustment. Study Design: The sample studied comprised 34 patients suffering from chronic facial pain in which the EMG activity of both masseters was recorded by electromyography. By selective grinding we alleviated all the occlusal interferences during the mandibular …

AdultMalemedicine.medical_specialtyOcclusal AdjustmentOdontologíaElectromyographyBite ForceDiagnostic Self EvaluationYoung AdultPhysical medicine and rehabilitationFacial PainmedicineHumansIn patientProspective StudiesFacial painProspective cohort studyGeneral DentistryOcclusal AdjustmentOral Medicine and Pathologymedicine.diagnostic_testElectromyographyResearchMyofascial painChronic painMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludBite force quotientTreatment OutcomeOtorhinolaryngologyTherapy Computer-AssistedUNESCO::CIENCIAS MÉDICASFemaleSurgeryChronic PainPsychologyFollow-Up Studies
researchProduct

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.

2004

An important purpose of postmarketing surveillance of drugs is to better characterize the safety profile of drug therapy in the clinical setting. Another goal is to confirm the effectiveness of these drugs in patients who are candidates for antihypertensive therapy and who may have been excluded from Phase III studies. Irbesartan is a long-acting angiotensin II-receptor blocker specific for the angiotensin 1-receptor subtype that, in clinical trials in patients with hypertension, reduces blood pressure.The KARTAN (this word was derived from the first and last syllables of Karvea [trademark of Bristol-Myers Squibb Group, Madrid, Spain] and irbesartan) study was designed to confirm and extend…

AdultMalemedicine.medical_specialtyPostmarketing surveillanceTetrazolesBlood PressurePharmacologyIrbesartanHeart RateRisk FactorsInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)Prospective cohort studyAntihypertensive AgentsAgedPharmacologyAged 80 and overbusiness.industryBiphenyl CompoundsIrbesartanMiddle AgedAngiotensin IIClinical trialBlood pressureTolerabilitySpainHypertensionObservational studyFemalebusinessmedicine.drugClinical therapeutics
researchProduct

Differential associations of cognitive insight components with pretreatment characteristics in first-episode psychosis

2014

An increasing number of studies have focused on cognitive insight (i.e. awareness of one's own thinking) in psychotic disorders. However, little is known about the premorbid and pretreatment correlates of cognitive insight in the early course of psychosis. One hundred and three patients experiencing first-episode psychosis (FEP) were assessed shortly after treatment initiation for cognitive insight. Pretreatment and baseline clinical, functional and neurocognitive characteristics were examined. The self-reflectiveness dimension of cognitive insight was independently associated with clinical insight and executive functioning, whereas self-certainty was associated with premorbid IQ, premorbid…

AdultMalemedicine.medical_specialtyPsychosisMetacognitionNeuropsychological TestsExecutive FunctionYoung AdultCognitionmedicineHumansYoung adultPsychiatryBiological PsychiatryCognitionAwarenessmedicine.diseaseExplained variationSelf ConceptPsychiatry and Mental healthCross-Sectional StudiesPsychotic DisordersSchizophreniaFemaleVerbal memoryPsychologySocial AdjustmentNeurocognitiveClinical psychologyPsychiatry Research
researchProduct

A randomised clinical trial to evaluate the acceptability and efficacy of an early phase, online, guided augmentation of outpatient care for adults w…

2019

AbstractBackgroundOutpatient interventions for adult anorexia nervosa typically have a modest impact on weight and eating disorder symptomatology. This study examined whether adding a brief online intervention focused on enhancing motivation to change and the development of a recovery identity (RecoveryMANTRA) would improve outcomes in adults with anorexia nervosa.MethodsParticipants with anorexia nervosa (n= 187) were recruited from 22 eating disorder outpatient services throughout the UK. They were randomised to receiving RecoveryMANTRA in addition to treatment as usual (TAU) (n= 99; experimental group) or TAU only (n= 88; control group). Outcomes were measured at end-of-intervention (6 w…

AdultMalemedicine.medical_specialtySocial adjustmentAdolescentPsychological interventionAnorexia nervosa; augmentation; early symptom change; feasibility; guidance; motivation; online; recovery; self-help; trialAnxietyBody Mass IndexYoung AdultrecoveryAmbulatory caremotivationSettore M-PSI/08 - Psicologia ClinicaaugmentationmedicineHumansAnorexia nervosa augmentation early symptom change feasibility guidance motivation online recovery self-help trialearly symptom changeself-helpApplied PsychologyonlineInternetbusiness.industryAnorexia nervosatrialClinical trialSelf CarePsychiatry and Mental healthAnorexia nervosa (differential diagnoses)Physical therapyAnxietyFemalemedicine.symptomEarly phasebusinessBody mass indexguidancefeasibility
researchProduct

Symptoms of adjustment disorder and smoking predict long-term functional outcome after ankle and lower leg fracture

2020

Objective To examine the psychological, social, behavioural and injury-related factors impacting functional outcome in patients with ankle or lower limb fracture one year post-operation. Methods In this prospective study 66 patients with ankle or lower leg fracture were recruited and followed up one year post-operation. Possible associations between predictors and functional outcome were explored by regression analyses. Functional outcome was assessed with the American Orthopedic Foot and Ankle Society Ankle-Hindfoot Score. Results Linear regression models revealed that smoking and elevated symptoms of adjustment disorder were associated with lower functional outcome one year post-operation…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentAdjustment disordersPhysical Therapy Sports Therapy and Rehabilitationrecovery of functionOutcome (game theory)functional outcomeLower leg fractureankle fracturesAdjustment DisordersFractures BoneYoung AdultLinear regressionmedicineHumansAnkle InjuriesProspective StudiesProspective cohort studyAgedRehabilitationbusiness.industryadjustmentlcsh:RM1-950SmokingRehabilitationpsychosocial factors.General MedicineMiddle Agedmedicine.diseaselcsh:Therapeutics. PharmacologyTreatment Outcomemedicine.anatomical_structureOrthopedic surgeryPhysical therapyFemaleAnklebusinessLeg InjuriesJournal of Rehabilitation Medicine
researchProduct

Early intervention with cognitive behavioral therapy reduces sick leave duration in people with adjustment, anxiety and depressive disorders

2018

Background: Early intervention in workers diagnosed with mental disorders is associated with a lower incidence of relapse and shorter sick leave. However, no studies have been carried out on the effect of early intervention using an evidence-based therapy, Cognitive Behavioral Therapy (CBT), on people with sick leave.Aims: The objectives of the present study are to study whether the type of intervention (early or late) will affect the total duration of the sick leave, the partial duration of the sick leave, the duration of the psychotherapy and the time until return to work after the psychotherapy ends. The sample was composed of 167 participants who were on sick leave for adjustment disord…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAdjustment disordersReturn to workAffect (psychology)Adjustment Disorders03 medical and health sciencesReturn to Work0302 clinical medicineIntervention (counseling)HumansMedicine030212 general & internal medicineDuration (project management)PsychiatryAgedDepressive DisorderCognitive Behavioral Therapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAnxiety Disorders030227 psychiatryCognitive behavioral therapyPsychiatry and Mental healthSpainSick leaveAnxietyFemaleSick Leavemedicine.symptombusinessJournal of Mental Health
researchProduct